Dose Escalation Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Single Agent IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
Latest Information Update: 22 Jan 2024
At a glance
- Drugs Izumerogant (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Proof of concept
- Sponsors Immunic
- 15 Jan 2024 Status changed from recruiting to discontinued.
- 31 Jan 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Mar 2023.
- 04 Aug 2022 According to an Immunic nedia release, the company plans to provide a more comprehensive update on safety and also on potential signs of anti-tumor activity of IMU-935 in this trial as soon as data from the planned dose expansion part are available.